In an effort to streamline the regulatory procedures for biopharmaceutical companies involved in the development of vaccines, recombinant DNA products, and other biological substances, the Central Drugs Standard Control Organization (CDSCO) has introduced a new directive. This circular states that approvals granted by Institutional Biosafety Committees (IBSC) will now be recognized when seeking permission to produce test items for evaluation, analysis, and testing through Form CT-10. This applies specifically to cases where the test item is created using Category I and Category II Genetic Engineering (GE) Experiments as outlined in the Regulations and Guidelines for Recombinant DNA Research and Biocontainment from 2017.
Form CT-10 is the official application that organizations or research institutions submit to the CDSCO, specifically the Drug Controller General of India’s office, to obtain authorization for the production of new drugs or investigational drugs for the purpose of testing, examination, or analysis. This recent decision by the CDSCO follows the recommendations put forth during the 314th Review Committee on Genetic Manipulation (RCGM) meeting held on July 9, 2025.
The Regulations and Guidelines for Recombinant DNA Research and Biocontainment, 2017 specify that Category I experiments can be initiated after notifying the IBSC, while Category II experiments require approval from the IBSC and an intimation to the RCGM before commencement. On the other hand, Category III and higher GE experiments necessitate prior authorization from the IBSC and subsequent approval from the RCGM, following the submission of relevant information in the prescribed format.
It is important to note that Category I and Category II GE experiments conducted in laboratories do not mandate RCGM approval. The guidelines emphasize that the regulatory pathways defined in the Regulations and Guidelines for Recombinant DNA Research and Biocontainment, 2017 should be adhered to for such experiments.
Despite these established regulations, it has been observed that biopharmaceutical industries continue to submit Form C1 for RCGM evaluation to conduct research and development (R&D). Subsequently, they attach the RCGM approval letter to the CDSCO when seeking approval for examination, testing, and analysis, along with Form CT-10.
To simplify this process, the RCGM has formally requested that IBSC approvals from Biopharma industries be accepted for the submission of Form CT-10. This is particularly relevant when seeking permission to manufacture test items for evaluation, testing, and analysis involving Category I and Category II GE Experiments as defined in the Regulations and Guidelines for Recombinant DNA Research and Biocontainment, 2017.
As the biopharmaceutical industry continues to advance and innovate, the importance of efficient regulatory processes cannot be overstated. The recent decision by the CDSCO to accept IBSC approvals for certain types of experiments marks a significant step towards streamlining procedures and reducing unnecessary bureaucratic hurdles. By acknowledging the expertise and oversight provided by IBSCs, the regulatory framework becomes more responsive and adaptive to the evolving landscape of biopharmaceutical research.
One of the key aspects of this regulatory adjustment is the alignment with international best practices in biopharmaceutical research and development. By recognizing the validity and rigor of IBSC approvals, the CDSCO is moving towards a more harmonized approach that fosters innovation while maintaining stringent safety standards. This shift not only benefits biopharmaceutical companies by expediting the approval process but also ensures that regulatory bodies can focus on high-risk experiments that truly require their oversight.
Furthermore, this move by the CDSCO highlights a shift towards a more collaborative and cooperative relationship between regulatory authorities and industry stakeholders. By leveraging the expertise of IBSCs and recognizing their role in ensuring biosafety and compliance, the regulatory process becomes more agile and responsive. This collaborative approach fosters trust and transparency, essential elements in the successful advancement of biopharmaceutical research and development.
In conclusion, the recent decision by the CDSCO to accept IBSC approvals for certain biopharmaceutical research activities represents a progressive step towards enhancing regulatory efficiency and fostering innovation in the sector. By simplifying the approval process for Category I and Category II GE Experiments, the CDSCO is promoting a more agile and responsive regulatory environment that supports the growth of the biopharmaceutical industry in India. This collaborative approach between regulatory authorities, industry stakeholders, and research institutions sets a positive precedent for future regulatory developments in the biopharmaceutical sector, ultimately benefiting patients, researchers, and the industry as a whole.
- Streamlining of regulatory procedures for biopharmaceutical research
- Acceptance of IBSC approvals for certain experiments by CDSCO
- Emphasis on collaborative relationship between regulatory authorities and industry
- Alignment with international best practices in biopharmaceutical R&D
- Promotion of innovation while maintaining safety standards
- Focus on agility and responsiveness in the regulatory framework
Tags: biopharma, regulatory
Read more on medicaldialogues.in